Galapagos is dedicated to conducting clinical trials that accurately measure the safety and efficacy of its investigational drugs. The Company abides by the highest ethical standards in conducting its clinical research, as described by the World Medical Association in the Declaration of Helsinki. Galapagos designs its trials to deliver robust and relevant data.
Galapagos conducts Phase 1 trials in healthy volunteers in centers which are specifically equipped for this purpose, with the aim to test the safety, tolerability and pharmacokinetics of the investigational drug. In cases where the Phase 1 outcome is positive, Galapagos has initiated Phase 2 studies which are conducted in patients, to preliminary measure efficacy suggesting effectiveness and also determine common short-term side effects and risks. These studies are performed by medical doctors who are specialists in the disease area. Galapagos is not allowed to be in any way involved in volunteer/patient enrollment for the conducted clinical trials: whether or not an individual can be included in a clinical study is decided only by the responsible medical doctors after having checked numerous eligibility criteria. In each case, Galapagos cannot and will not influence the specialists' decisions for such inclusion. The patient should contact his/her treating physician, who can then investigate with the clinical study centers the possibility for the patient to be included in a clinical study.
Information about ongoing clinical trials for Galapagos’ investigational drugs is available at clinicaltrials.gov, a service of the U.S. National Institutes of Health that provides details on clinical trials conducted worldwide.
For more information about ongoing clinical trials for: